A Role for IGF-1R–Targeted Therapies in Small-Cell Lung Cancer?
- 1 January 2011
- journal article
- Published by Elsevier BV in Clinical Lung Cancer
- Vol. 12 (1), 38-42
- https://doi.org/10.3816/clc.2011.n.005
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Defining the pathway to insulin-like growth factor system targeting in cancerBiochemical Pharmacology, 2010
- Prognostic role of insulin‐like growth factor receptor‐1 expression in small cell lung cancerAPMIS, 2009
- Phase II Study of the Anti–Insulin-Like Growth Factor Type 1 Receptor Antibody CP-751,871 in Combination With Paclitaxel and Carboplatin in Previously Untreated, Locally Advanced, or Metastatic Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2009
- Selective inhibition of SCLC growth by the A12 anti-IGF-1R monoclonal antibody correlates with inhibition of AktLung Cancer, 2008
- Targeting receptor tyrosine kinase signalling in small cell lung cancer (SCLC): What have we learned so far?Cancer Treatment Reviews, 2007
- The Insulin-Like Growth Factor-I Receptor Kinase Inhibitor, NVP-ADW742, Sensitizes Small Cell Lung Cancer Cell Lines to the Effects of ChemotherapyClinical Cancer Research, 2005
- Role of the Insulin-Like Growth Factor I/Insulin Receptor Substrate 1 Axis in Rad51 Trafficking and DNA Repair by Homologous RecombinationMolecular and Cellular Biology, 2003
- Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesisCancer Cell, 2002
- Serum insulin-like growth factor-I levels in patients with small cell lung cancerEuropean Journal of Cancer and Clinical Oncology, 1988
- Insulin-like growth factor-I can mediate autocrine proliferation of human small cell lung cancer cell lines in vitro.JCI Insight, 1988